An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial

Trial Profile

An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms BARRIER-P
  • Most Recent Events

    • 11 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 21 Dec 2015 Planned initiation date changed from 1 Jun 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.
    • 06 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top